Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Intec Pharma Ltd. (NASDAQ:NTEC), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation of the two firms.
Earnings and Valuation
We can see in table 1 the earnings per share, top-line revenue and valuation of Ionis Pharmaceuticals Inc. and Intec Pharma Ltd.
Table 2 demonstrates the net margins, return on assets and return on equity of Ionis Pharmaceuticals Inc. and Intec Pharma Ltd.
Ionis Pharmaceuticals Inc. and Intec Pharma Ltd. Ratings and Recommendations are available in the next table.
Ionis Pharmaceuticals Inc.’s downside potential currently stands at -18.54% and an $68.33 average target price.
Institutional Insider Ownership
Ionis Pharmaceuticals Inc. and Intec Pharma Ltd. has shares owned by institutional investors as follows: 89.1% and 39.64%. 0.2%